5:2 Stock split; Record Date Jan 8; Small-Cap Pharma Stock Delivers 110% Gains in 6Months; Buy or Wait?

A small-cap pharmaceutical player, Jagsonpal Pharmaceuticals, has announced the record date for the subdivision of its stocks. With a market cap of 1904 crore, the company continues to be a strong player in the pharmaceutical industry. investors and market watchers are keeping a close eye on the stock post the announcements of the split.

Stock Split Announcement

The Board of Directors of Jagsonpal Pharmaceuticals has announced the subdivision of its equity shares. A resolution approving the stock split was passed through a circular resolution on Tuesday, December 17, 2024. Following the shareholders' approval via postal ballot on Wednesday, December 11, 2024, the company has finalized the record date for the stock split as Wednesday, January 8, 2025.

As per the exchange filing, one equity share with a face value of Rs. 5/- (Rupees five only) will be subdivided into equity shares with a face value of Rs. 2/- (Rupee two only), fully paid up. This move aims to enhance the stock's liquidity and make it more accessible to a broader investor base.

Jagsonpal Pharmaceuticals Share Performance

Jagsonpal Pharma's shares have consistently delivered remarkable returns to investors across various timeframes. Following the stock split announcement, the share price opened at Rs. 720, with a modest increase of 0.28% compared to the previous day's close.

Over the past month, the stock has witnessed a sharp appreciation of 21%, due to strong market momentum. In the last six months alone, the stock has surged by an astounding 110%, offering multibagger returns and significantly rewarding its shareholders.

Seeing the long-term performance, Jagsonpal Pharma has delivered extraordinary returns. Over the past five years, the stock has appreciated by a staggering 2,700%, turning into a wealth multiplier for its investors. Since its initial listing, the share price has soared by an incredible 6,745%, showing the company's strong growth.

Financial Performance

In Q2 FY25, the company reported a net profit of Rs. 11.46 crore for the quarter ended September 2024, a significant increase of 53.41% compared to the same period last year. Quarterly sales reached Rs. 74.69 crore, marking a 29.15% rise from Rs. 57.83 crore in the corresponding quarter of the previous year, which reflects its operational efficiency and strong market demand for its products.

About Jagsonpal Pharmaceuticals

Established in 1972, Jagsonpal Pharmaceuticals is a small-cap company specializing in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients.